Biotech Investors Reach $32.5M Deal Over Failed COVID Test

By Gina Kim · October 1, 2024, 6:03 PM EDT

A class of Talis Biomedical Corp. investors accusing the company of inflating their stock price in the run-up to its IPO and then failing to launch a COVID-19 diagnostic test asked...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Settlement

Case Information

Case Title

IN RE Talis Biomedical Securities Litigation

Case Number

Court

California Northern

Nature of Suit

Securities/Commodities

Date Filed

January 07, 2022

Recent Articles By Gina

November 19, 2024
Costco Shoppers Say Kirkland Fish Oil Pills Hide Heart Risks
November 12, 2024
Masimo Can't Tie Alleged IP Theft To Apple Profits, Expert Says
November 08, 2024
Apple Didn't Hire Cercacor CTO To Steal Watch IP, Ex-VP Says
November 07, 2024
Masimo Spinoff's Ex-CTO Denies Giving Apple Trade Secrets
November 06, 2024
Masimo Expert Cites LED And Foam As Evidence Apple Stole IP
November 05, 2024
Apple Stole Masimo Sensor IP, Calif. Judge Told At Trial's Start
October 23, 2024
ICE, Nonprofits End FOIA Row Over Alleged Sterilization Docs
October 07, 2024
AbbVie's Top Brass Escape Suit Over Rinvoq Claims, For Now
October 02, 2024
Pfizer Didn't Warn Of Tumor Risks In Depo-Provera, Suit Says
October 01, 2024
Premier Health Sued For Age Bias By Ex-Regional Director